No connection

Search Results

BIAF vs MLEC

BIAF
bioAffinity Technologies, Inc.
BEARISH
Price
$1.35
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%
MLEC
Moolec Science SA
BEARISH
Price
$7.52
Market Cap
$5.5M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BIAF
--
MLEC
--
Forward P/E
BIAF
-2.25
MLEC
-31.33
P/B Ratio
BIAF
0.52
MLEC
10.76
P/S Ratio
BIAF
0.9
MLEC
--
EV/EBITDA
BIAF
0.09
MLEC
--

Profitability

Gross Margin
BIAF
27.86%
MLEC
0.0%
Operating Margin
BIAF
-158.56%
MLEC
0.0%
Profit Margin
BIAF
-217.5%
MLEC
0.0%
ROE
BIAF
-245.18%
MLEC
--
ROA
BIAF
-71.71%
MLEC
--

Growth

Revenue Growth
BIAF
-38.5%
MLEC
--
Earnings Growth
BIAF
--
MLEC
--

Financial Health

Debt/Equity
BIAF
0.08
MLEC
--
Current Ratio
BIAF
3.65
MLEC
--
Quick Ratio
BIAF
3.44
MLEC
--

Dividends

Dividend Yield
BIAF
--
MLEC
--
Payout Ratio
BIAF
0.0%
MLEC
0.0%

AI Verdict

BIAF BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.

Strengths
Strong liquidity position with Current Ratio of 3.65 and Quick Ratio of 3.44
Low leverage with Debt/Equity ratio of only 0.08
Positive gross margin of 27.86%, indicating some pricing power or cost control at production level
Risks
Critically low Piotroski F-Score of 1/9 signals high risk of financial failure
Massive and sustained profitability deficits: Operating Margin of -158.56%, ROA of -71.71%
Revenue declining sharply by 38.5% year-over-year, indicating deteriorating business fundamentals
MLEC BEARISH

MLEC exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across nearly all health metrics. The company is currently pre-revenue with 0.00% margins and a catastrophic price trajectory, losing 93% of its value over the last year and 99.5% over five years. With no Graham Number or Intrinsic Value calculable due to the lack of earnings and revenue, the stock is trading as a highly speculative micro-cap with deteriorating momentum.

Strengths
Recent quarterly EPS surprises have been positive relative to low expectations
Operates in the high-innovation Biotechnology sector
Low absolute share price may attract high-risk speculative traders
Risks
Extreme bankruptcy risk implied by a 1/9 Piotroski F-Score
Complete absence of revenue and profit margins
Severe capital erosion with a 5-year price decline of 99.5%

Compare Another Pair

BIAF vs MLEC: Head-to-Head Comparison

This page compares bioAffinity Technologies, Inc. (BIAF) and Moolec Science SA (MLEC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile